Drug & Poison Information Channel

Important Note on Escitalopram Oxalate: * Prior to initiation, screen patients for a personal family history of bipolar disorder, mania, or hypomania [2]. * Discontinue MAOIs intended to treat psychiatric disorders at least 14 days prior to the administration of escitalopram. Allow at least 14 days to elapse between discontinuation of escitalopram and initiation of MAOIs intended to treat psychiatric disorders [3]. * Do not initiate escitalopram in a patient receiving linezolid or IV methylene blue. If a patient is already receiving escitalopram and treatment with linezolid or IV methylene blue is unavoidable, and the potential benefit of therapy outweighs the risk for serotonin syndrome, discontinue escitalopram. Monitor for symptoms of serotonin syndrome for 2 weeks or for 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. Resume escitalopram therapy 24 hours after the last dose of linezolid or IV methylene blue

Alzheimer’s Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer’s Disease and Type 2 Diabetes: Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910482/)

Experts in cyber security related to healthcare recommend taking five actions to prevent cyber-attacks. These include making risk assessments of new devices, adhering to general security procedures and guidelines, grant access to devices only to authorised users, disable the device´s connection to the internet or allow only certain internet sites to connect to devices, and use effective tools that support internet security. (Gloss 2020.)

Three categories that classify smart health technology used in healthcare: Application-oriented (data transfer between detectors and mobile apps), things-oriented (intelligent processing, tracking in real-time), and semantics-oriented (develop behavioural patterns based on data acquired) (Sundaravadivel, Kougianos, Mohanty & Ganapathiraju 2018, 1-10.)

The FDA has granted accelerated approval for Madrigal Pharmaceuticals's (US) Rezdiffra (resmetirom) for patients with nonalcoholic steatohepatitis (NASH), now referred to as metabolic dysfunction-associated steatohepatitis (MASH), with stage II and III liver fibrosis. The FDA has said a liver biopsy to determine a patient's eligibility for Rezdiffra is not required. Rezdiffra works by activating the thyroid hormone beta-receptor to reduce liver fat, inflammation, fibrosis, and blood cholesterol. Approval was based on a Phase III MAESTRO-NASH study that met both primary endpoints. The Phase III study demonstrated no worsening of fibrosis in 25.9% and 29.9% of patients receiving either 80mg or 100mg, respectively, compared to 9.7% in those who received placebo. In addition, 24.2% and 25.9% of patients on the two Rezdiffra doses, respectively, had fibrosis reduction with no worsening of the nonalcoholic fatty liver disease (NAFLD) activity score, compared to 14.2% in the placebo group. Madrigal provided additional safety data from the MAESTRO-NAFLD-1 trial, which showed the drug is well tolerated and offers significant improvements on biomarkers such as liver fat and triglycerides. No incidence of drug-induced liver injury was found, a concerning side effect found in previous MASH drug candidate rejections. Madrigal commented that the wholesale acquisition cost of Rezdiffra will be $47,400 before any discounts.

The US Food and Drug Administration (FDA) has approved the anti-obesity drug semaglutide 2.4 mg injection (Wegovy) for reducing cardiovascular risk in adults with overweight or obesity and established cardiovascular disease. The label expansion now includes use of the once-weekly glucagon-like peptide 1 (GLP-1) agonist for reducing risks for major adverse cardiovascular events (MACEs) including cardiovascular death, nonfatal heart attack, or nonfatal stroke. The drug is indicated for use in combination with a reduced calorie diet and increased physical activity. Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight. The approval was based on results from the 3-year SELECT trial, which randomly assigned 17,604 patients with cardiovascular disease and body mass index ≥ 27 to weekly semaglutide or placebo. None of the patients had diabetes, although two thirds met prediabetes criteria. The incidence of MACEs was reduced by 20% with the drug. The label will also reflect the risk reduction of 15% for cardiovascular death and 19% for death from any cause. Participants also lost a mean of 9.4% of body weight over the first 2 years with semaglutide vs 0.88% with placebo. The makers of the weight loss medication, Novo Nordisk, has also filed for a label expansion in the European Union, with a decision expected in 2024. Wegovy was first approved by the FDA in 2021 for chronic weight management: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m2 (obesity), or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia) and pediatric patients ≥12 years of age with an initial BMI at the ≥95th percentile standardized for age and sex (obesity).

How to cite a website?!! https://www.google.com/search?sca_esv=de3b8b35270c999b&sxsrf=ACQVn094CmN3uAeFWFCODY_vmBqajf-s1A:1707897333573&q=How+to+cite+a+website&tbm=vid&source=lnms&sa=X&ved=2ahUKEwi1moWvraqEAxXy_AIHHYsiD-QQ0pQJegQIDRAB&biw=1536&bih=738&dpr=1.25#fpstate=ive&vld=cid:14a7fcfe,vid:RbxF3Am3DNk,st:0